Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report third-quarter results on Oct. 31, 2024. The Zacks Consensus Estimate for revenues is pegged at $3.67 billion, while the same for earnings is pinned at $11.75 per share. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. REGN Faces Decline in Eylea Sales, Dupixent Fuels Growth Regeneron is currently facing challenges for its lead drug, Eylea, which is its primary growth engine. A significant chunk of Regeneron's rev ...

The biotech sector represents companies developing innovative treatments and therapies using biological processes. These firms range from early-stage research companies to established pharmaceutical developers. Biotech stocks offer investment opportunities in companies working on groundbreaking medical solutions. The sector spans various therapeutic areas, from cancer treatments to rare diseases. Investing in biotech stocks can provide exposure to potentially revolutionary medical breakthroughs. Successful ...

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved wellcontrolled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the US suffer from chronic spontaneous urticaria ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the U.S. suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, Oct. 24, 2024 (GLOBE ...

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the Phase 3 PHOTON trial presented at AAO Patients switched to EYLEA HD experienced substantially slower fluid reaccumulation, as compared to their previous rate of fluid reaccumulation with EYLEA® (aflibercept) Injection 2 mg The consistent achievement of much longer dosing intervals with EYLEA HD – together with ...

Regeneron (REGN) has been on a downward spiral lately with significant selling pressure. After declining 11.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have gained 13.5% in the year so far against the industry’s decline of 2.8%.The stock has outperformed the sector during this timeframe but underperformed the S&P 500 Index.REGN Outperforms Industry & SectorImage Source: Zacks Investment ResearchRegeneron’s efforts to diversify its portfolio have impressed its investors, even as lead drug Eylea faces challenges.Regeneron’s EYLEA HD Stabilizes Ophthalmology UnitEylea is an anti-vascular endothelial growth fact ...

Core Viewpoint - Regeneron Pharmaceuticals has faced challenges with its key product Eylea, particularly due to competition and recent regulatory developments, which have impacted its stock price significantly [1] Group 1: Eylea Overview - Eylea is a treatment for wet age-related macular degeneration (AMD), with Regeneron holding U.S. licensing rights and sharing international rights with Bayer [2] - The approval of Vabysmo, a competing drug by Roche, in early 2022 marked the beginning of challenges for Eylea [2] - Regeneron introduced a higher-dose formulation of Eylea, which has helped maintain its market position against Vabysmo [2] Group 2: Financial Performance - In Q2, combined U.S. sales of Eylea and its higher-dose version reached $1.53 billion, a 2% increase year-over-year, with the higher-dose contributing $304 million [3] - Regeneron's total revenue for the same quarter was $3.55 billion, reflecting a 12% increase compared to the previous year, with Eylea sales accounting for 43% of total revenue [3] Group 3: Competitive Landscape - The FDA approved Pavblu, a biosimilar for Eylea's original formulation, and a recent court ruling favored Amgen, allowing them to potentially launch Pavblu [4] - Regeneron is appealing the court's decision, indicating ongoing legal battles regarding Eylea's patent exclusivity [4] Group 4: Future Outlook - The potential loss of patent exclusivity for Eylea could negatively impact Regeneron, but the company has other growth drivers, including the eczema treatment Dupixent, which saw a 27% revenue increase to $3.56 billion in Q2 [5][6] - Dupixent's recent approval for treating chronic obstructive pulmonary disease (COPD) is expected to significantly boost its sales [6] - Regeneron has a robust pipeline with over 50 programs, particularly focusing on oncology, which may help mitigate the impact of Eylea's challenges [6]

  Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placeboDupixen ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo Dupixent is the leading biologic medicine for all of its FDA ...